| Authors: |
Rathgeber AC; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.; Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, Berlin, Germany., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nagler A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li S; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, USA., Dorfman DM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Bullinger L; Department of Hematology, Oncology, and Cancer Immunology, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), partner site Berlin, Berlin, Germany., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Livak KJ; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Ludwig LS; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, USA.; Harvard Medical School, Boston, USA., Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. livius.penter@charite.de.; Department of Hematology, Oncology, and Cancer Immunology, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany. livius.penter@charite.de.; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. livius.penter@charite.de.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Berlin, Germany. livius.penter@charite.de. |
